Literature DB >> 25037082

Inclusion body myositis.

Mazen M Dimachkie1, Richard J Barohn2.   

Abstract

The idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of rare disorders that share many similarities. In addition to sporadic inclusion body myositis (IBM), these include dermatomyositis, polymyositis, and autoimmune necrotizing myopathy. IBM is the most common IIM after age 50 years. Muscle histopathology shows endomysial inflammatory exudates surrounding and invading nonnecrotic muscle fibers often accompanied by rimmed vacuoles and protein deposits. It is likely that IBM is has a prominent degenerative component. This article reviews the evolution of knowledge in IBM, with emphasis on recent developments in the field, and discusses ongoing clinical trials.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnosis; Idiopathic inflammatory myopathies; Inclusion body myositis; Pathology; Pathophysiology; Polymyositis; Prognosis; Treatment

Mesh：

Year:  2014        PMID： 25037082      PMCID： PMC4115580          DOI： 10.1016/j.ncl.2014.04.001

Source DB:  PubMed          Journal:  Neurol Clin        ISSN： 0733-8619            Impact factor:   3.806


  71 in total

Review 1.  Inclusion body myositis.

Authors:  Rabi Tawil; Robert C Griggs
Journal:  Curr Opin Rheumatol       Date:  2002-11       Impact factor: 5.006

2.  Inclusion Body Myositis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

3.  Myeloid dendritic cells in inclusion-body myositis and polymyositis.

Authors:  Steven A Greenberg; Geraldine S Pinkus; Anthony A Amato; Jack L Pinkus
Journal:  Muscle Nerve       Date:  2007-01       Impact factor: 3.217

4.  A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities.

Authors:  Fieke M Cox; Maarten J Titulaer; Jacob K Sont; Axel R Wintzen; Jan J G M Verschuuren; Umesh A Badrising
Journal:  Brain       Date:  2011-09-09       Impact factor: 13.501

5.  Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients.

Authors:  Umesh A Badrising; Marion L C Maat-Schieman; Johannes C van Houwelingen; Peter A van Doorn; Sjoerd G van Duinen; Baziel G M van Engelen; Carin G Faber; Jessica E Hoogendijk; Aeiko E de Jager; Peter J Koehler; Marianne de Visser; Jan J G M Verschuuren; Axel R Wintzen
Journal:  J Neurol       Date:  2005-06-17       Impact factor: 4.849

6.  Long-term observational study of sporadic inclusion body myositis.

Authors:  Olivier Benveniste; Marguerite Guiguet; Jane Freebody; Odile Dubourg; Waney Squier; Thierry Maisonobe; Tanya Stojkovic; Maria Isabel Leite; Yves Allenbach; Serge Herson; Stefen Brady; Bruno Eymard; David Hilton-Jones
Journal:  Brain       Date:  2011-10-12       Impact factor: 13.501

7.  Inclusion body myositis: explanation for poor response to immunosuppressive therapy.

Authors:  R J Barohn; A A Amato; Z Sahenk; J T Kissel; J R Mendell
Journal:  Neurology       Date:  1995-07       Impact factor: 9.910

8.  Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM.

Authors:  Nizar Chahin; Andrew G Engel
Journal:  Neurology       Date:  2007-09-19       Impact factor: 9.910

9.  Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and β-amyloid in the muscle.

Authors:  Jana Zschüntzsch; Joachim Voss; Kim Creus; Stephan Sehmisch; Raghavan Raju; Marinos C Dalakas; Jens Schmidt
Journal:  Arthritis Rheum       Date:  2012-12

10.  Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases.

Authors:  M Needham; I James; A Corbett; T Day; F Christiansen; B Phillips; F L Mastaglia
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-02-07       Impact factor: 10.154
View more
  18 in total

Review 1.  Update on Inclusion Body Myositis.

Authors:  Duaa Jabari; V V Vedanarayanan; Richard J Barohn; Mazen M Dimachkie
Journal:  Curr Rheumatol Rep       Date:  2018-06-28       Impact factor: 4.592

2.  A Patient with Sjogren's Syndrome and Subsequent Diagnosis of Inclusion Body Myositis and Light-Chain Amyloidosis.

Authors:  Jason Hom; Shruti Marwaha; Anna Postolova; Jessie Kittle; Rosaline Vasquez; Jean Davidson; Jennefer Kohler; Annika Dries; Liliana Fernandez-Betancourt; Marta Majcherska; Joanna Dearlove; Shyam Raghavan; Hannes Vogel; Jonathan A Bernstein; Paul Fisher; Euan Ashley; Jacinda Sampson; Matthew Wheeler
Journal:  J Gen Intern Med       Date:  2019-03-18       Impact factor: 5.128

Review 3.  Myositis Mimics.

Authors:  E Harlan Michelle; Andrew L Mammen
Journal:  Curr Rheumatol Rep       Date:  2015-10       Impact factor: 4.592

Review 4.  Inclusion Body Myositis: Update on Pathogenesis and Treatment.

Authors:  Elie Naddaf; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

5.  Immunophenotyping of Inclusion Body Myositis Blood T and NK Cells.

Authors:  Namita A Goyal; Gérald Coulis; Jorge Duarte; Philip K Farahat; Ali H Mannaa; Jonathan Cauchii; Tyler Irani; Nadia Araujo; Leo Wang; Marie Wencel; Vivian Li; Lishi Zhang; Steven A Greenberg; Tahseen Mozaffar; S Armando Villalta
Journal:  Neurology       Date:  2022-02-07       Impact factor: 9.910

Review 6.  Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies.

Authors:  Namita A Goyal; Tahseen Mozaffar
Journal:  Curr Treat Options Neurol       Date:  2018-07-23       Impact factor: 3.598

7.  The spectrum of idiopathic inflammatory myopathies in South Africa.

Authors:  Keith J Chinniah; Girish M Mody
Journal:  Clin Rheumatol       Date:  2020-03-24       Impact factor: 2.980

8.  Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies.

Authors:  Inka Albrecht; Cecilia Wick; Åsa Hallgren; Anna Tjärnlund; Kanneboyina Nagaraju; Felipe Andrade; Kathryn Thompson; William Coley; Aditi Phadke; Lina-Marcela Diaz-Gallo; Matteo Bottai; Inger Nennesmo; Karine Chemin; Jessica Herrath; Karin Johansson; Anders Wikberg; A Jimmy Ytterberg; Roman A Zubarev; Olof Danielsson; Olga Krystufkova; Jiri Vencovsky; Nils Landegren; Marie Wahren-Herlenius; Leonid Padyukov; Olle Kämpe; Ingrid E Lundberg
Journal:  J Clin Invest       Date:  2015-11-09       Impact factor: 14.808

9.  Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT.

Authors:  Anthony A Amato; Michael G Hanna; Pedro M Machado; Umesh A Badrising; Hector Chinoy; Olivier Benveniste; Ananda Krishna Karanam; Min Wu; László B Tankó; Agnes Annette Schubert-Tennigkeit; Dimitris A Papanicolaou; Thomas E Lloyd; Merrilee Needham; Christina Liang; Katrina A Reardon; Marianne de Visser; Dana P Ascherman; Richard J Barohn; Mazen M Dimachkie; James A L Miller; John T Kissel; Björn Oskarsson; Nanette C Joyce; Peter Van den Bergh; Jonathan Baets; Jan L De Bleecker; Chafic Karam; William S David; Massimiliano Mirabella; Sharon P Nations; Hans H Jung; Elena Pegoraro; Lorenzo Maggi; Carmelo Rodolico; Massimiliano Filosto; Aziz I Shaibani; Kumaraswamy Sivakumar; Namita A Goyal; Madoka Mori-Yoshimura; Satoshi Yamashita; Naoki Suzuki; Masashi Aoki; Masahisa Katsuno; Hirokazu Morihata; Kenya Murata; Hiroyuki Nodera; Ichizo Nishino; Carla D Romano; Valerie S L Williams; John Vissing; Lixin Zhang Auberson
Journal:  Neurology       Date:  2021-02-17       Impact factor: 9.910

Review 10.  Emerging therapeutic options for sporadic inclusion body myositis.

Authors:  Lindsay N Alfano; Linda P Lowes
Journal:  Ther Clin Risk Manag       Date:  2015-09-25       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.